team-Javad-Shahedi

Javad Shahidi MD MSc

Chief Medical Officer

Dr. Javad Shahidi, MD, MSc, serves as Chief Medical Officer at Centessa Pharmaceuticals. In the past 10+ years, Javad has held increasing responsibilities in Clinical Development at Bayer, Eli Lilly and Company and Daiichi Sankyo. Most recently, he led the development of ENHERTU® from its first-in-human studies through its rapid expansion leading to several regulatory submissions and approvals around the world.

Javad earned his MD in Tehran and his MSc in Experimental Medicine from McGill University in Montreal.

Scroll to Top
;
pipeline chart header registrational white
SerpinPC

Overview
SerpinPC is a subcutaneously administered novel inhibitor of APC being developed as a potential treatment for hemophilia, regardless of severity or inhibitor status, and may also prevent bleeding associated with other bleeding disorders. Centessa is advancing the registrational program for SerpinPC in hemophilia B, which includes a set of clinical studies with multiple components. PRESent-5, initiated in late 2022, is an observational feeder study to collect prospective observational data for minimum defined periods before switching to dosing subjects in the interventional studies. The interventional studies include PRESent-2 (moderately severe to severe hemophilia B without inhibitors, and severe hemophilia A with and without inhibitors) and PRESent-3 (hemophilia B with inhibitors). Additional information on the trials can be accessed at www.clinicaltrials.gov  (NCT05605678NCT05789524NCT05789537). SerpinPC is an investigational agent that has not been approved by the FDA or any other regulatory authority.

Reason to Believe in Target
Human Genetics Support

Epidemiology
~20,000 persons with hemophilia in the United States
450,000 estimated global prevalence
Disease

Hemophilia B